1 Delta variants of SARS-CoV-2 cause significantly increased

2 vaccine breakthrough COVID-19 cases in Houston, Texas

4 5	Paul A. Christensen, ^{*,†,‡} Randall J. Olsen, ^{*,†,‡} S. Wesley Long, ^{*,†,‡} Sishir Subedi, [†] James
6	J. Davis, ^{§,¶} Parsa Hodjat, [†] Debbie R. Walley, [†] Jacob C. Kinskey, [†] Matthew Ojeda
7	Saavedra, [†] Layne Pruitt, [†] Kristina Reppond, [†] Madison N. Shyer, [†] Jessica Cambric, [†]
8	Ryan Gadd, [†] Rashi M. Thakur, [†] Akanksha Batajoo, [†] Regan Mangham, [†] Sindy Pena, [†]
9	Trina Trinh, [†] Prasanti Yerramilli, [†] Marcus Nguyen, ^{§,¶} Robert Olson, ^{§,¶} Richard Snehal, [†]
10	Jimmy Gollihar, ^{†,#} James M. Musser. ^{†,‡,**}
11	
12	*Contributed equally;
13	[†] Laboratory of Human Molecular and Translational Human Infectious Diseases, Center
14	for Infectious Diseases, Houston Methodist Research Institute and Department of
15	Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas 77030;
16	[‡] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College,
17	1300 York Avenue, New York City, New York 10065;
18	$^{\$}$ Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801
19	South Ellis Avenue, Chicago, Illinois, 60637;

- ²⁰ [¶]Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South
- 21 Cass Avenue, Lemont, Illinois, 60439;
- ²² [#]DEVCOM Army Research Laboratory-South, Austin, Texas 78712

23

- ^{**}Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology
- 25 and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,
- 26 Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:
- 27 jmmusser@houstonmethodist.org

28

29 Running head: Delta variants and vaccine breakthrough

30

31 Disclosures: None.

32

- 33 Number of text pages: 15
- 34 Number of tables: 3
- 35 Number of figures: 4

36

- 37 Funding: This project was supported by the Houston Methodist Academic Institute
- Infectious Diseases Fund; and supported in whole or in part with federal funds from the
- 39 National Institute of Allergy and Infectious Diseases, National Institutes of Health,
- 40 Department of Health and Human Services, under Contract No. 75N93019C00076

41 (J.J.D. and R.O.).

43 Abstract

44 Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 45 pandemic. Delta variants of concern are now the focus of intense international attention 46 because they are causing widespread COVID-19 disease globally and are associated 47 with vaccine breakthrough cases. We sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston 48 49 Methodist hospital system. This sample represents 91% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April 50 51 onward to cause 99.9% of all COVID-19 cases and spread throughout the Houston 52 metroplex. Compared to all other variants combined, Delta caused a significantly higher 53 rate of vaccine breakthrough cases (23.7% for Delta compared to 6.6% for all other 54 variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low 55 56 median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was 57 closely similar to the median Ct value for unvaccinated patients with COVID-19 caused 58 by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant 59 60 differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and 61 deaths. 62

- 63 [Introduction]
- 64
- 65
- 66 Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY.3, and AY.4
- are the focus of intense international concern because they are causing widespread
- 68 COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere
- 69 (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-
- 70 info.html, last accessed: August 18, 2021;
- 71 <u>https://www.gov.uk/government/collections/new-sars-cov-2-variant</u>, last accessed:
- August 18, 2021)¹. For example, Delta has replaced the Alpha variant in the United
- 73 Kingdom, previously the cause of virtually all COVID-19 cases in that country
- 74 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
- 75 <u>13-july-2021</u>, last accessed August 18, 2021;
- 76 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions
- 77 and diseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed
- August 18, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also
- ⁷⁹ have become of considerable public health and biomedical concern worldwide²⁻⁶. To
- 80 study Delta spread and vaccine breakthrough cases in metropolitan Houston, we
- sequenced the genomes of 16,965 SARS-CoV-2 from patient samples acquired March
- 15, 2021 through September 20, 2021 using an Illumina NovaSeq 6000 instrument and
- 83 methods described previously^{7, 8}. This period includes the time from initial identification
- 84 of Delta-related VOCs in late April in our large Houston Methodist healthcare system
- until Delta VOCs continuously caused the supermajority (99.9%) of all new cases. The
- sequenced sample is 91% of the 18,736 total COVID-19 cases diagnosed in our health
- 87 system during the study period. We also compared characteristics of patients infected

- 88 with Alpha and Delta VOCs, an analysis that identified several significant differences
- 89 between patients infected with these two variants.

90

91

- 92 Materials and Methods
- 93
- 94 Patient Specimens

95

Specimens were obtained from registered patients at Houston Methodist hospitals. 96 associated facilities (e.g., urgent care centers), and institutions in the Houston 97 metropolitan region that use our laboratory services. The great majority of individuals 98 99 had signs or symptoms consistent with COVID-19 disease. For analyses focusing on 100 the Delta family variants, a comprehensive sample of genomes obtained from March 15, 101 2021 through September 20, 2021 was used. This time frame was chosen because it represents the period during which the downturn of our third wave was occurring, and 102 103 soon after we identified the first Delta variant case in our health care system. 104 Subsequently, Delta variants increased rapidly to continuously cause 99.9% of all new 105 cases. The study included 16,965 unique patients identified in this time frame for whom 106 we had SARS-CoV-2 genome sequences. For analyses comparing features of patients 107 infected with the Delta variants and Alpha VOC, a comprehensive sample of genomes 108 obtained from January 1, 2021 through September 20, 2021 was used. This time frame 109 represents the period during which we identified the first Alpha variant case in our

110	health care system. This VOC increased rapidly and peaked, and then decreased to
111	cause less than 1% of all cases in the region. This part of the study included 28,560
112	unique patients identified in the January 1, 2021 through September 20, 2021 period.
113	The work was approved by the Houston Methodist Research Institute Institutional
114	Review Board (IRB1010-0199).
115	
116	SARS-CoV-2 Molecular Diagnostic Testing
117	
118	Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
119	were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
120	using assays granted Emergency Use Authorization (EUA) from the FDA
121	(https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
122	diagnostic-testing-sars-cov-2#offeringtests, last accessed June 7, 2021). Multiple
123	molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
124	BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
125	GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-
126	2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using
127	the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic
128	Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
129	and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were
130	performed on material obtained from nasopharyngeal swabs immersed in universal
131	transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
132	sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

- 133 collection methods were used (https://vimeo.com/396996468/2228335d56, last
- 134 <u>accessed June 7, 2021</u>).
- 135
- 136 SARS-CoV-2 Genome Sequencing
- 137
- 138 Libraries for whole SARS-CoV-2 genome sequencing were prepared according to
- 139 version 3 or version 4 (<u>https://community.artic.network/t/sars-cov-2-version-4-scheme-</u>
- 140 <u>release/312</u>, last accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing
- 141 protocol. Our semi-automated workflow described previously^{7, 8} employed BioMek i7
- 142 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS automated
- 143 liquid handlers (FORMULATRIX). Short sequence reads were generated with a
- 144 NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis in the
- study period, we included some genome sequences reported in a recent publication.⁸
- 146
- SARS-CoV-2 Genome Sequence Analysis and Identification of Variants
 148
- 149 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
- 150 (https://www.bv-brc.org/app/ComprehensiveSARS2Analysis, last accessed June 7,
- 151 2021, requires registration). The One Codex SARS-CoV-2 variant calling and
- 152 consensus assembly pipeline was used to assemble all sequences
- 153 (<u>https://github.com/onecodex/sars-cov-2.git</u>, last accessed June 7, 2021) using default
- parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-
- 155 r116 for sequence trimming (<u>https://github.com/lh3/seqtk.git</u>, last accessed June 7,

156	2021); minimap version 2.1 for aligning reads against reference genome Wuhan-Hu-1
157	(NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar
158	version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and
159	variants of interest (VOIs) were identified based on genome sequence data and
160	designated by Pangolin v. 3.1.11 with pangoLEARN module 2021-08-09 (https://cov-
161	lineages.org/resources/pangolin.html, last accessed August 18, 2021).
162	There is a known problem with the ARTIC V3 primer set that results in lack of
163	detection or ambiguity of the G142D and D950N single nucleotide variants, even though
164	these amino acid changes (142D and 950N) are present in the overwhelming majority of
165	B.1.617.2 Delta variant isolates (https://community.artic.network/t/sars-cov-2-version-4-
166	scheme-release/312, last accessed September 1, 2021, https://outbreak.info/compare-
167	lineages?pango=B.1.617.2&gene=S&threshold=0.2, last accessed September 1, 2021).
168	After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes
169	contained both 142D and 950N polymorphisms except for four isolates, two of which
170	lacked 142D and two which lacked 950N. We recently reported an analysis that
171	confirmed the previously identified ARTIC V3 problem ⁹ . Thus, for the Delta isolates
172	presented here, virtually all samples sequenced with ARTIC V3 are presumed to have
173	G142D and D950N.
174	
175	Patient Metadata and Geospatial Analysis

176

Patient metadata (Table 1, Table 2, Table 3) were acquired from the electronic medical
record by standard informatics methods. Patient home address zip codes were used to

179	visualize the geospatial distribution of spread for each VOC and VOI. Figures were
180	generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA). A
181	vaccination breakthrough case was defined as a PCR-positive sample from a patient
182	obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or
183	Moderna mRNA vaccines) was completed. For some cases, manual chart review was
184	conducted to resolve discrepancies or ambiguities.
185	
186	
187	Results
100	
188	
189	Delta Epidemiologic Wave
190	
191	The first Houston Methodist patient infected with a Delta family variant was identified in
192	mid-April 2021, a time when the Alpha VOC was responsible for most COVID-19 cases
193	in metropolitan Houston, and the area was experiencing a steady downturn in total
194	number of new COVID-19 cases (Figure 1). Delta VOCs slowly increased in frequency,
195	but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs
196	occurred (Figure 1, Figure 2), with an estimated doubling time of approximately seven
197	days. By September 20, the genome data showed that Delta VOCs accounted for
198	99.9% of all new COVID-19 cases in our health system (Figure 2). This represents the
199	fourth wave of COVID-19 cases in metropolitan Houston (Figure 1).
200	During the study period 18,736 COVID-19 cases were diagnosed in our
201	healthcare system, and we sequenced 16,965 SARS-CoV-2 genomes, representing

202	91% of cases.	. We identified	13,043 patient	، (76.9% of the total)	sequenced) with Delta
-----	---------------	-----------------	----------------	------------------------	-----------------------

- VOCs (Table 1A). The majority (62%; 2,418 of 3,922) of the non-Delta COVID-19 cases
- 204 occurring during the study period were caused by the Alpha (UK B.1.1.7) VOC.
- 205 Consistent with extensive infections caused by Delta variants in Southeast Asia
- 206 and elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-
- 207 <u>surveillance/variant-info.html</u>, last accessed: August 18, 2021;

208 <u>https://www.gov.uk/government/collections/new-sars-cov-2-variant</u>, last accessed:

August 18, 2021)¹, several patients had very recent travel histories to countries with a

high prevalence of these VOCs, suggesting acquisition abroad and importation into

Houston. Sixty patients with Delta Plus (Delta plus the K417N spike amino acid

substitution) were identified.

213 To understand the geospatial distribution of Delta in metropolitan Houston, we 214 acquired patient metadata from the electronic medical record by standard informatics 215 methods, and home address zip codes were used to visualize virus spread (Figure 2). 216 Delta VOCs were widely distributed throughout metropolitan Houston, with 334 distinct 217 zip codes represented (Figure 2), indicative of the ability of Delta variants to spread 218 very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination 219 over time illustrated the rapid spread of these variants throughout the Houston 220 metroplex (Figure 2).

221

222 Delta Family Subvariants

224 A total of 1,236 subvariants was identified based on amino acid changes in spike protein. The seven most common identified in our study are shown (Figure 3) and these 225 226 represented 73% of the 13,043 Delta samples. It is possible that the unexpectedly high 227 number of subvariants reflects several contributing factors, including the large 228 population sizes and genetic diversity of Delta globally, and multiple independent 229 introductions into the Houston area. Other factors that in principle may contribute to 230 subvariant generation and survival include high virus load in patients on initial diagnosis 231 (**Table 1**), infection of partially immunized hosts, and prolonged infections occurring in relatively immunocompromised individuals¹⁰⁻¹⁶. In this regard, some of our patients had 232 233 a history of cancer and organ transplants (data not shown). Patients infected with the same subvariant usually lived in different zip codes and generally had no apparent 234 235 epidemiological link, consistent with the ability of Delta to spread very rapidly. In some 236 cases there were clear epidemiologic links between patients infected with the same 237 subvariant, including being members of the same household.

There is a considerable lack of detailed information about patients in the UnitedStates with COVID-19 caused by Delta VOCs

240 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---

<u>13-july-2021</u>, last accessed August 18, 2021). Compared to all other patients in the time
frame studied, there was no significant difference in sex, but patients infected with Delta
were significantly but modestly younger (**Table 1**). However, Delta variant patients were
admitted significantly less frequently than other patients and had a significantly longer
median hospital length of stay, but there was no significant difference in mortality rate
(**Table 1**). Delta cases were more likely to be Asian (consistent with multiple recent

247	entry points from abroad) and Caucasian and less likely to be Hispanic or Latino, have
248	significantly lower PCR cycle threshold (Ct) values on initial diagnosis (a proxy for
249	higher virus load, a finding consistent with increased transmissibility of Delta variants).
250	In addition, Delta variants caused a significantly much higher rate of vaccine
251	breakthrough cases (23.7% compared to 6.6% for all other variants combined) (Table
252	1). Consistent with Delta causing an increased number of vaccine breakthrough cases,
253	it has been reported that this variant has reduced sensitivity to antibody neutralization in
254	vitro ¹⁴ .
255	
256	Comparison of Delta and Alpha COVID-19 Cases
257	
258	The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the
259	Alpha VOC (Figure 1) provided the opportunity of compare and contrast large disease
260	waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we
261	included Alpha VOC cases beginning January 1, 2021, because that time was soon
262	after our first recorded Houston Methodist case caused by this variant. The number of
263	Delta cases studied (n = 13,043) was much greater than the number of Alpha cases (n
264	= 3,238) (Table 2). The two patient populations differed significantly in many
265	characteristics, including median age, ethnicity, median PCR Ct level, admission rates,
266	maximum respiratory support, rate of vaccine breakthrough, median length of stay, and
267	mortality (Table 2).
268	

269 Vaccine Breakthrough Cases

270

271	We next analyzed vaccine breakthrough cases (Table 3). We found 3,346 of the 16,965
272	total patients (19.7%) for whom we have genome sequence data met the CDC definition
273	of vaccine breakthrough cases (Table 1 and Table 3). There was no simple relationship
274	between the time elapsed since administration of the second booster vaccination and
275	the date of vaccination breakthrough (data not shown). These 3,346 patients received
276	either the Pfizer-BioNTech BNT162b2 ($n = 2,829, 85\%$), Moderna mRNA-1273 ($n =$
277	365, 11%), or J&J/Janssen JNJ-78436735 ($n = 147, 4\%$) vaccine; vaccine type was not
278	specified for five individuals. This distribution generally reflects the great majority of
279	BNT162b2 vaccination doses given in our health system and should not be interpreted
280	to mean that the Pfizer-BioNTech and Moderna products are unusually prone to
281	breakthrough cases, as these mRNA vaccines are highly efficacious ^{6, 17-23} . Vaccinated
282	patients infected with non-Delta variants had a significantly higher Ct value on initial
283	diagnosis, likely indicating better vaccine protection, lower virus load, and decreased
284	probability of transmission. Compared to all other variants combined, a significantly
285	lower percentage (25.9% compared to 37.2%; P=0.0001) of patients with breakthrough
286	cases caused by Delta variants was admitted to the hospital (Table 1 and Table 3).
287	

288 Lambda and Mu Variants of Interest

289

The Lambda variant of interest was first reported in November 2020. It has very recently attracted widespread media and public interest because it has caused large numbers of infections in Peru and Ecuador, and has been reported to cause COVID-19 in the U.S^{24,}

293 ²⁵ (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, last accessed 294 September 2, 2021). There has been speculation that Lambda may become numerically 295 prominent in the United States and other countries, in part because its spike protein 296 differs immunologically and has been reported to be partially resistant in vitro to vaccine-induced sera and therapeutic monoclonal antibodies²⁶⁻²⁸. Because of this 297 298 concern, we inspected our large genome sequence database to determine if Lambda 299 was present, and if so, had it increased substantially in the Houston metropolitan region. 300 The analysis identified only eight cases caused by this variant of interest, the first one 301 identified in our Houston Methodist patient population in mid-July 2021 (Figure 4A). These patients lived in several non-contiguous zip codes throughout the metroplex, that 302 303 is, were not restricted to a single geographic area of greater Houston (Figure 4A, B). 304 The Mu VOI was initially identified in Colombia in January, 2021, and has been reported to account for 39% of cases in that country²⁹. Mu also has been found in many other 305 306 countries worldwide, and recently it was reported that the Mu variant has increased 307 resistance in vitro to antibodies elicited by vaccination with BNT162b2 and natural infection by SARS-CoV-2³⁰. We identified 53 cases of COVID-19 caused by the Mu 308 309 VOI, and similar to the Lambda these cases were distributed in multiple areas in the Houston metropolitan region (Figure 4C, D). 310

311

312 Discussion

314 In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient 315 characteristics for 16,965 patients, focusing on mid-March 2021 through late September 2021, a time frame in which there was total replacement of the previously dominant 316 317 Alpha (B.1.1.7) VOC by Delta family VOCs. During this six-month period, a substantial 318 increase in COVID-19 cases occurred in our healthcare system and throughout all of 319 the Houston metropolitan area, virtually all driven by rapid dissemination of the highly 320 contagious Delta family variants. The study was based predominantly on genome 321 sequence analysis of 16,965 SARS-CoV-2 samples from socioeconomically, 322 geographically, and ethnically diverse patients. Several key findings were made, including (i) Delta family VOCs supplanted the Alpha VOC in a relatively short period of 323 324 time, (ii) regardless of vaccination status, on initial diagnosis, compared to patients 325 infected by other VOCs, patients infected by Delta VOCs had significantly lower Ct 326 values, likely indicating significantly higher viral load in the nasopharynx, (iii) Delta 327 caused significantly more vaccine breakthrough cases than other VOCs, (iv) 328 significantly fewer fully vaccinated individuals required hospitalization, (v) the Lambda 329 and Mu VOIs were identified but were very rare, and they did not increase to substantial 330 levels in the time frame studied. Our genome sequence data document a rapid increase of Delta variant cases in 331

metropolitan Houston and a corresponding decrease of COVID-19 cases caused by
 Alpha and other variants, findings similar to epidemiologic trends observed in the UK
 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-- <u>13-july-2021</u>, last accessed August 18, 2021;

336 <u>https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions</u>

anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed
August 18, 2021). In less than five months, Delta VOCs increased from an initial
documented case in our large patient population to cause 99.9% of all cases in our
healthcare system. The rapid increase in Delta cases we documented is responsible for
a prominent fourth wave of COVID-19 disease in Houston that is ongoing (Figure 1).
Our findings are consistent with Delta VOCs epidemiologic data reported from other
regions of the US.

344 We found that Delta was significantly more likely to cause vaccine breakthrough 345 cases (Table 1 and Table 3). However, importantly, 19.7% of all of our 16,965 COVID-346 19 cases with genome sequence data occurred in fully vaccinated individuals, but 347 importantly only a small number (n = 896; 5.3%) of these patients required 348 hospitalization. Vaccine breakthrough cases have emerged as an area of great interest, 349 especially so with the increasing percentage of COVID-19 cases caused by Delta variants and the recognition that they are important causes of breakthroughs³¹⁻³⁶. 350 351 Although our analysis did not identify a simple relationship between the time elapsed 352 since administration of the second booster vaccination and the date of vaccination 353 breakthrough, this is an important area for continued study. Similarly, we did not study 354 the potential relationship between vaccination breakthrough and waning immunity, but 355 studies of this topic are ongoing.

Some investigators have speculated that the Lambda and Mu variants may become a major concern in future surges. Although in principle this is possible, our data show that neither variant has increased substantially in our metropolitan area during the

359	time frame studied. Thus, our genome analysis of a large set of samples from the first
360	nine months of 2021 does not currently support this speculation, although
361	circumstances may change in the future. Because we are sequencing the genome of
362	the great majority of SARS-CoV-2 causing COVID-19 in our diverse patient population,
363	we are continuously monitoring the growth trajectory of these and other variants in a
364	major metropolitan region in the US. Thus, our ongoing near-real-time sequencing of
365	SARS-CoV-2 genomes responsible for COVID-19 cases in metropolitan Houston
366	provides a facile strategy to assess changes in the virus population composition and
367	molecular evolution in this populous area.
368	Our study has several limitations that should be noted. Although we sequenced
369	the genomes of SARS-CoV-2 causing 91% of all Houston Methodist COVID-19 cases in

the study period, this sample represents only approximately 5% of cases reported in the

371 metropolitan region. We believe it is possible that our patient populations

372 underrepresent certain demographic groups, for example including homeless individuals

and pediatric patients. The great majority of the samples sequenced in this study were

obtained from symptomatic patients. Thus, it is possible that our sample failed to identify

375 virus genotypes that are preferentially represented in asymptomatic individuals.

However, given that at the end of the study Delta represented 99.9% of all cases, we

377 think it unlikely that variants associated with asymptomatic individuals would be

378 substantially different, although this is a formal possibility.

In the aggregate, our data add critical new information to the finding that these
three vaccines are highly efficacious in decreasing severe COVID-19 disease,

381	hospitalizations, and deaths ^{6, 20, 23} . Further, the present study highlights the importance
382	of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and
383	stresses the need to continue to do this in near-real time as the pandemic continues,
384	the virus evolves, and new variants with potentially increased fitness are generated.
385	Analyses of this type are also important in the context of vaccine formulation and long
386	COVID, an increasing health and economic problem globally.

387

388

389 Acknowledgments

390

391 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha 392 Pejerrey for editorial contributions and Dr. Heather McConnell for help with figures. The 393 research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James J. Davis was 394 funded in whole or in part with Federal funds from the National Institute of Allergy and 395 396 Infectious Diseases, National Institutes of Health, Department of Health and Human 397 Services, under Contract No. 75N93019C00076. The funders had no role in the design 398 and conduct of the study; collection, management, analysis, and interpretation of the 399 data; preparation, review, or approval of the manuscript; and decision to submit the 400 manuscript for publication.

401 The findings and conclusions in this article are those of the authors and do not 402 necessarily reflect the views of the U.S. Army.

- 403 We declare that we have no conflict of interest.
- 404
- 405

406 Author Contributions

408	P.A.C., R.J.O., S.V	N.L., S.S.,	and J.M.M. had fu	Ill access to all stud	y data and take
-----	---------------------	-------------	-------------------	------------------------	-----------------

- responsibility for the integrity of the data and the accuracy of the data analysis; concept
- and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
- 411 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
- 412 by P.A.C.; funding obtained by J.M.M. and J.J.D.; overall supervision by J.M.M; P.A.C.,
- 413 R.J.O., and S.W.L. contributed equally and are co-first authors.
- 414
- 415
- 416 Institutional Review Board statement: This work was approved by the Houston
- 417 Methodist Research institutional review board (IRB1010-0199).
- 418
- 419
- 420 Additional Information: Genome data used in this study have been deposited to421 GISAID.

422 **References**

- 424 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, Fatihi S,
- 425 Datta M, Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V,
- 426 Singh MK, Imran M, Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V,
- 427 Chaudhary U, Thukral L, Pandey R, Dash D, Faruq M, Lall H, Gogia H, Madan P,
- 428 Kulkarni S, Chauhan H, Sengupta S, Kabra S, Consortium TIS-C-G, Singh SK, Agrawal
- 429 A, Rakshit P: Genomic characterization and Epidemiology of an emerging SARS-CoV-2
- 430 variant in Delhi, India. medRxiv 2021:2021.06.02.21258076.
- 431 [2] Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-
- 432 Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC,
- 433 Hatziioannou T, Bieniasz PD, Darnell RB: Vaccine Breakthrough Infections with SARS-
- 434 CoV-2 Variants. N Engl J Med 2021, 384:2212-8.
- [3] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M,
- 436 Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad
- 437 H, Rahav G, Wiener-Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of
- 438 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021.
- 439 [4] COVID-19 Vaccine Breakthrough Infections Reported to CDC United States,
- 440 January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021, 70:792-3.
- [5] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R,
- Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron
- 443 O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M,
- 444 Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A:

- 445 Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in
- 446 BNT162b2-mRNA-vaccinated individuals. Nat Med 2021, Aug;27(8):1379-1384.
- [6] Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM,
- 448 Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager
- 449 DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning
- 450 DJ, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CT, Busse L, Ten
- 451 Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C,
- 452 Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring AS, Grijalva
- 453 CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart
- 454 KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH:
- 455 Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations
- in the United States. Clin Infect Dis 2021.
- 457 [7] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,
- 458 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,
- 459 Musser JM: Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome
- 460 Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence
- 461 and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. Am J
- 462 Pathol 2021, 191:983-92.
- [8] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,
- 464 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd
- 465 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of
- 466 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,

- Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol
 2021, 191(10):1754-1773.
- 469 [9] Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, Shukla M, Subedi S,
- 470 Stevens R, Musser JM: Analysis of the ARTIC version 3 and version 4 SARS-CoV-2
- 471 primers and their impact on the detection of the G142D amino acid substitution in the
- 472 spike protein. bioRxiv 2021:2021.09.27.461949.
- [10] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic
- 474 V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J: SARS-CoV-2 evolution in an
- immunocompromised host reveals shared neutralization escape mechanisms. Cell
- 476 2021, 184:2605-17.e18.
- [11] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo
- 478 HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins
- 479 M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S,
- 480 Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD,
- 481 Seaman MS, Cernadas M, Li JZ: Persistence and Evolution of SARS-CoV-2 in an
- 482 Immunocompromised Host. N Engl J Med 2020, 383:2291-3.
- [12] Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus
- 484 CE, Adams M, Washer L, Martin ET, Lauring AS: Prolonged Severe Acute Respiratory
- 485 Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis
 486 2021, 223:23-7.
- 487 [13] Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps
- 488 A, Sobolewski MD, Rennick LJ, Macatangay BJC, Klamar-Blain C, Kitsios GD, Methé B,
- 489 Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee J,

- 490 Sethi R, Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Vignali DA, Duprex WP, Agha
- 491 ME, Mellors JW, McCormick KD, Morris A, Haidar G: Intractable Coronavirus Disease
- 492 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2
- 493 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy
- 494 Recipient: A Case Study. Clinical Infectious Diseases 2021, 73(3):e815-e821.
- [14] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM,
- 496 Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le
- 497 Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H,
- 498 Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey
- 499 FA, Schwartz O: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
- 500 neutralization. Nature 2021, 596(7871):276-280.
- 501 [15] Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A: SARS-CoV-2
- 502 evolution during treatment of chronic infection. Nature 2021, 592:277-82.
- 503 [16] Ghedin E, Nussenblatt V, Roder A, Das S, de Wit E, Youn J-H, Banakis S,
- 504 Muchegian A, Mederos C, Wang W, Chung M, Perez-Perez L, Palmore T, Brudno J,
- 505 Kochenderfer J: Year-long COVID-19 infection reveals within-host evolution of SARS-
- 506 CoV-2 in a patient with B cell depletion. medRxiv 2021:2021.10.02.21264267.
- 507 [17] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL,
- 508 Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury
- 509 K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A,
- 510 Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC: Safety
- and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of
- 512 Medicine 2020, 383:2603-15.

513	[18] Baden LR	, El Sahly HM	, Essink B, Kotloff	K, Frey S,	Novak R, Dieme	ert D, Spector
-----	---------------	---------------	---------------------	------------	----------------	----------------

- 514 SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro
- 515 C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M,
- 516 Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C,
- Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T: Efficacy and Safety of
- the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020, 384:403-16.
- [19] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B,
- 520 Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-
- Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie
- 522 L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath
- 523 PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD,
- 524 Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ,
- 525 Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi
- 526 YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy
- 527 MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E,
- 528 Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans
- J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC,
- 530 Pollard AJ: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
- 531 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
- 532 Africa, and the UK. Lancet 2021, 397:99-111.
- [20] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe
- J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G,
- 535 Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M: Effectiveness of

- 536 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021, 385:585-537 594.
- 538 [21] Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19
- 539 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021, 385:187-9.
- 540 [22] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch
- 541 M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
- 542 Vaccination Setting. N Engl J Med 2021, 384:1412-23.
- 543 [23] Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M,
- 544 Nutalapati C, Kulkarni A, Mukherjee P, Zaveri L, Team CC-, Team AHC-Vs, Tallapaka
- 545 KB, Reddy DN: Clinical outcomes in vaccinated individuals hospitalized with Delta
- 546 variant of SARS-CoV-2. medRxiv 2021:2021.07.13.21260417.
- 547 [24] Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena
- 548 L, Morales Ruiz S, Acedo S, Lizarraga W, Bailon H, Cáceres O, Galarza M, Rojas-
- 549 Serrano N, Vargas-Herrera N, Lope-Pari P, Huayra J, Solari L: Genomic analysis
- reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in
- 551 Peru despite circulation of variants of concern. J Med Virol 2021, 1-5.
- [25] Romero PE, Dávila-Barclay A, Salvatierra G, González L, Cuicapuza D, Solis L,
- 553 Marcos-Carbajal P, Huancachoque J, Maturrano L, Tsukayama P: The Emergence of
- 554 SARS-CoV-2 Variant Lambda (C.37) in South America. medRxiv
- 555 2021:2021.06.26.21259487.
- [26] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR: The Spike
- 557 Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial

- 558 Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv
- 559 2021:2021.05.14.444076.
- 560 [27] Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y,
- 561 Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Takaori-Kondo A, Arase
- 562 H, Consortium TGtPJ, Saito A, Nakagawa S, Sato K: SARS-CoV-2 Lambda variant
- 563 exhibits higher infectivity and immune resistance. bioRxiv 2021:2021.07.28.454085.
- [28] Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, Liu J, Chen Z, Waheed
- 565 H, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: The Lambda
- variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.
- 567 bioRxiv 2021:2021.08.25.457692.
- 568 [29] Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro
- JA, Prada DA, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J,
- 570 Santamaría G, Rivera J, Rojas P, Ortiz JH, Cardona A, Malo D, Prieto-Alvarado F,
- 571 Gómez FR, Wiesner M, Martínez MLO, Mercado-Reyes M. Characterization of the
- 572 emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021,
- 573 95:105038.
- [30] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A,
- 575 Consortium TGtPJ, Nakagawa S, Sato K: Ineffective neutralization of the SARS-CoV-2
- 576 Mu variant by convalescent and vaccine sera. bioRxiv 2021:2021.09.06.459005.
- [31] Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N,
- 578 Foreman A, Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B,
- 579 Park DJ, Siddle KJ, Harik V, Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS:
- 580 Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough

- 581 Infections, Associated with Large Public Gatherings Barnstable County,
- 582 Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021, 70:1059-62.
- 583 [32] Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, Cui L,
- 584 Kalimuddin S, Chia WN, Tan CW, Ann Chai LY, Tan SY, Zheng S, Pin Lin RT, Wang L,
- 585 Leo Y-S, Lee VJ, Lye DC, Young BE: Virological and serological kinetics of SARS-CoV-
- 586 2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv
- 587 2021:2021.07.28.21261295.
- 588 [33] Sheikh A, McMenamin J, Taylor B, Robertson C: SARS-CoV-2 Delta VOC in
- 589 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet
- 590 2021, 397:2461-2.
- [34] Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian
- 592 A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH,
- 593 Friedrich TC, Grande KM: Shedding of Infectious SARS-CoV-2 Despite Vaccination.
- 594 medRxiv 2021:2021.07.31.21261387.
- [35] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal
- Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y,
- 597 Regev-Yochay G: Covid-19 Breakthrough Infections in Vaccinated Health Care
- 598 Workers. N Engl J Med 2021.
- [36] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo
- 600 R, Alroy-Preis S, Ash N, Huppert A: Waning immunity of the BNT162b2 vaccine: A
- nationwide study from Israel. medRxiv 2021:2021.08.24.21262423.
- 602
- 603

604 Figure Legends

605

606	Figure 1 Epidemiologic curve showing four COVID-19 disease waves in Houston
607	Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-
608	three-day moving average. Each of the four waves is shown in a different color simply
609	as a stylistic device. The first and second waves were composed of a heterogenous
610	array of SARS-CoV-2 genotypes. The Alpha variant shown in the third wave and the
611	Delta variant shown in the fourth indicate their numeric prominence in those waves, and
612	should not be interpreted to mean that all cases in the third and fourth waves were
613	caused by Alpha and Delta VOCs, respectively. The fourth wave shown includes data
614	through September 20, 2021. The figure was generated with Tableau version 2020.3.4
615	(Tableau Software, LLC, Seattle, WA). The curve mirrors that of disease activity in
616	metropolitan Houston, Texas.
617	
618	Figure 2 Increase in Delta frequency over time and distribution in metropolitan
619	Houston. The study time frame was March 15, 2021 through September 20, 2021. A:

Cumulative increase in Delta during the study period; y-axis is the cumulative number of
new COVID-19 cases. At the end of the study period, Delta continuously caused 99.9%
of all COVID-19 cases. B – E: Geospatial distribution of Delta based on home address
zip code for each patient. B: April 15 – May 15; C: April 15 – June 15; D: April 15 – July
15; E: April 15 – August 15; F: April 15 – September 20. Note differences in heat map
scale for each panel. Figures were generated using Tableau version 2020.3.4. (Tableau
Software, LLC, Seattle, WA).

628	Figure 3 Structural changes present in spike protein of the seven most abundant Delta
629	subvariants identified in the study. The numbers denote the number of patients with
630	each subvariant identified in this study. These seven subvariants represented 73% of
631	the 13,043 Delta samples identified in the study. In this figure, we included all
632	subvariants represented by at least 100 samples. S1-NTD, S1 domain-aminoterminal
633	domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain.
634	The figure is a modified version of one published previously ⁸ .
635	
636	Figure 4 Lambda and Mu variants identified in metropolitan Houston in our patient
637	population. A: cumulative increase in the cases caused by Lambda variants identified in
638	the study; B: geospatial distribution of these Lambda variants based on the home
639	address zip code for each patient. C: cumulative increase in cases caused by the Mu
640	variants identified in the study; D: geospatial distribution of the Mu variants based on
641	the home address zip code for each patient. Figures were generated using Tableau
642	version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

Table 1. Summary of pertinent patient metadata for the 16,965 unique patients

	Delta Variant	Other Variants	Total	Statistical Analysis	
No. (%) with data	13043 (76.9%)	3922 (23.1%)	16965		
Patient Characteristics					
Median Age (Years)	46.7	47.9	47.0	<i>P</i> =0.0114	
				Mann-Whitney	
Female	6986 (53.6%)	2033 (51.8%)	9019 (53.2%)	<i>P</i> =0.0578	
Male	6057 (46.4%)	1889 (48.2%)	7946 (46.8%)	Fisher's exact test	
Ethnicity	1		I		
Caucasian	5657 (43.5%)	1533 (39.4%)	7190 (42.6%)	<i>P</i> <0.0001	
Hispanic or Latino	3395 (26.1%)	1199 (30.8%)	4594 (27.2%)	Chi-square	
Black	2908 (22.4%)	913 (23.4%)	3821 (22.6%)	-	
Asian	493 (3.8%)	113 (2.9%)	606 (3.6%)	-	
Native American	24 (0.2%)	15 (0.4%)	39 (0.2%)	-	
Hawaiian/Pacific Islander	32 (0.2%)	6 (0.2%)	38 (0.2%)	-	
Unavailable	492 (3.8%)	116 (3.0%)	608 (3.6%)		
BMI		1		1	
Median BMI	29.6	30.3	29.8	<i>P</i> <0.0001	
				Mann-Whitney	
Admission Data					
Admitted	5184 (39.7%)	2118 (54.0%)	7302 (43.0%)	<i>P</i> <0.0001	
Not Admitted	7859 (60.3%)	1804 (46.0%)	9663 (57.0%)	Fisher's exact test	
				Odds Ratio	
				0 554 (95% CI 0 511-	
				0.600)	
Madian LOS (Dava)	5.7	5.0	5.2	<i>R</i> <0.0001	
Median LOS (Days)	5.7	5.0	5.3	Mann-Whitney	
Max Respiratory Support	1	1	1	1	
ECMO	16 (0.3%)	7 (0.3%)	23 (0.3%)	<i>P</i> <0.0001	
Mechanical Ventilation	555 (10.7%)	167 (7.9%)	722 (9.9%)	Chi-square	

Non-Invasive Ventilation	501 (9.7%)	187 (8.8%)	688 (9.4%)			
High Flow Oxygen	1450 (28.0%)	402 (19.0%)	1852 (25.4%)			
Low Flow Oxygen	1741 (33.6%)	876 (41.4%)	2617 (35.8%)			
Room Air	921 (17.8%)	479 (22.6%)	1400 (19.2%)			
Mortality						
Alive	12496 (95.8%)	3755 (95.7%)	16251 (95.8%)	<i>P</i> =0.8561		
Deceased	547 (4.2%)	167 (4.3%)	714 (4.2%)	Fisher's exact test		
				Odds Ratio:		
				0.896 (95% CI 0.739-		
				1.087)		
Median PCR Cycle Threshold						
Abbott Alinity	21.0	25.6	n=5608	<i>P</i> <0.0001		
	n=4200	n=1408		Mann-Whitney		
Hologic Panther	21.9	26.0	n=1613	<i>P</i> <0.0001		
	n=1140	n=473		Mann-Whitney		
Vaccine						
No vaccine	9483 (72.7%)	3509 (89.5%)	12992 (76.6%)	<i>P</i> <0.0001		
>7 days past 1st vaccine	472 (3.6%)	155 (4.0%)	627 (3.7%)	Chi-square		
>14 days past 2nd vaccine	3088 (23.7%)	258 (6.6%)	3346 (19.7%)			
Data include 16.965 unique par	tients with high-qualit	v sequence results b	etween March 15. 2	021 and September 20.		

644

645 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of

646 stay

Table 2. Comparison of pertinent patient metadata for 16,281 unique Delta VOC

648 and Alpha VOC patients

	Delta Variant	Alpha Variant	Total	Statistical Analysis		
No. (%) with data	13043 (80.1%)	3238 (19.9%)	16281			
Patient Characteristics	Patient Characteristics					
Median Age (Years)	46.7	49.4	47.3	<i>P</i> <0.0001		
				Mann-Whitney		
Female	6986 (53.6%)	1698 (52.4%)	8684 (53.3%)	<i>P</i> =0.2538		
Male	6057 (46.4%)	1540 (47.6%)	7597 (46.7%)	Fisher's exact test		
Ethnicity	I					
Caucasian	5657 (43.5%)	1269 (39.4%)	6926 (42.7%)	<i>P</i> <0.0001		
Hispanic or Latino	3395 (26.1%)	961 (29.8%)	4356 (26.9%)	Chi-square		
Black	2908 (22.4%)	757 (23.5%)	3665 (22.6%)			
Asian	493 (3.8%)	126 (3.9%)	619 (3.8%)			
Native American	24 (0.2%)	12 (0.4%)	36 (0.2%)			
Hawaiian/Pacific Islander	32 (0.2%)	4 (0.1%)	36 (0.2%)			
Unavailable	492 (3.8%)	91 (2.8%)	583 (3.6%)			
BMI						
Median BMI	29.6	30.5	29.8	<i>P</i> <0.0001		
				Mann-Whitney		
Admission Data	I					
Admitted	5184 (39.7%)	1721 (53.2%)	6905 (42.4%)	<i>P</i> <0.0001		
Not Admitted	7859 (60.3%)	1517 (46.8%)	9376 (57.6%)	Fisher's exact test		
				0.581 (95% CI 0.538-		
Median LOS (Deve)	E 7	E 4	E 4	D.028)		
Median LOS (Days)	5.7	5.1	5.4	Mann-Whitney		
Max Respiratory Support						
	16 (0.20/)	7 (0 40()	22 (0.20()	P-0.0001		
ECMO	16 (0.3%)	7 (0.4%)	23 (0.3%)	1 \0.0001		

			740 (40 00()		
Mechanical Ventilation	555 (10.7%)	155 (9.0%)	710 (10.3%)	Chi-square	
Non-Invasive Ventilation	501 (9.7%)	165 (9.6%)	666 (9.6%)		
High Flow Oxygen	1450 (28.0%)	366 (21.3%)	1816 (26.3%)		
Low Flow Oxygen	1741 (33.6%)	705 (41.0%)	2446 (35.4%)		
Room Air	921 (17.8%)	323 (18.8%)	1244 (18.0%)		
Mortality					
Alive	12496 (95.8%)	3073 (94.9%)	15569 (95.6%)	<i>P</i> =0.0271	
Deceased	547 (4.2%)	165 (5.1%)	712 (4.4%)	Fisher's exact test	
				Odds Ratio:	
				0.815 (95% CI 0.682-	
				0.975)	
Median PCR Cycle Threshold					
Abbott Alinity	21.0	22.4	n=5301	<i>P</i> =0.0004	
	n=4200	n=1101		Mann-Whitney	
Hologic Panther	21.9	24.3	n=1514	<i>P</i> <0.0001	
	n=1140	n=374		Mann-Whitney	
Vaccine					
No vaccine	9483 (72.7%)	2969 (91.7%)	12452 (76.5%)	<i>P</i> <0.0001	
>7 days past 1st vaccine	472 (3.6%)	133 (4.1%)	605 (3.7%)	Chi-square	
>14 days past 2nd vaccine	3088 (23.7%)	136 (4.2%)	3224 (19.8%)		

649

Data include 16,281 unique patients with high-quality sequence results between January 1, 2021 and September 20,

650 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of

651 stay

Table 3. Summary of pertinent patient metadata for the 3,346 fully vaccinated

653 patients

	Vaccinated	Not Vaccinated	Total	Statistical Analysis		
Median PCR Cycle Threshold						
Abbott Alinity	20.5	22.1	n=5608	<i>P</i> =0.0018		
	n=1244	n=4364		Mann-Whitney		
Hologic Panther	22.2	23.5	n=1613	<i>P</i> =0.0348		
	n=378	n=1235		Mann-Whitney		
Admission Data						
Admitted	896 (26.8%)	6406 (47.0%)	7302 (43.0%)	<i>P</i> <0.0001		
Not Admitted	2450 (73.2%)	7213 (53.0%)	9663 (57.0%)	Fisher's exact test		
				Odds Ratio:		
				0.412 (95% CI 0.379-0.448)		
	Delta Variant	Other Variants	Total			
No. (%) with data	3088 (92.3%)	258 (7.7%)	3346			
Admission Data						
Admitted	800 (25.9%)	96 (37.2%)	896 (26.8%)	<i>P</i> =0.0001		
Not Admitted	2288 (74.1%)	162 (62.8%)	2450 (73.2%)	Fisher's exact test		
				Udds Ratio:		
				0.590 (95% Cl 0.453-0.769)		







